Core Viewpoint - Guangdong Yidoli Biotechnology Co., Ltd. held an online investor meeting to discuss its mid-year performance and future strategies, focusing on product development and market expansion [1][2]. Group 1: Investor Relations Activity - The investor meeting took place on September 19, 2025, from 15:30 to 17:00 on the "Panorama Roadshow" website [2]. - Key personnel present included CEO Zhou Derong, independent director Yuan Ziqiang, CFO Huang Xiaoping, and board secretary Zhu Shanmin [2]. Group 2: Product Development and Market Strategy - The company has ceased production of Vitamin B12 due to market conditions and has made progress in animal plant extracts, completing various trials and obtaining new product certificates for red clover and stone mint extracts [2]. - In the human plant extract segment, the company developed multiple new products and optimized extraction processes, aiming for significant sales growth in overseas markets, with preparations for its German subsidiary completed [2]. Group 3: Production Capacity and Marketing - In 2024, the company produced 41,533 tons of biological enzyme preparations and sold 42,383 tons, achieving near full capacity utilization [2]. - The company is investing in new and upgraded projects across four bases to increase production capacity, while also expanding its global market presence by registering products in over 30 countries and establishing long-term partnerships with more than 2,300 quality clients [2]. Group 4: Shareholder Information and Market Management - As of September 10, 2025, the company had 20,222 shareholders [2]. - The management is focusing on core business development, research innovation, global market expansion, and efficiency improvements to achieve performance growth and high-quality development, alongside cash dividends, share buybacks, and equity incentives for market value management [2].

Core Insights - The article highlights the establishment of the Yuelu Mountain Laboratory as a significant national strategic initiative aimed at advancing traditional Chinese medicine and agricultural biotechnology [2][6][12] Group 1: Laboratory Overview - Yuelu Mountain Laboratory encompasses 41,000 square meters of space with 17 buildings, housing over 200 high-level research teams and more than 2,000 researchers [3][6] - The laboratory aims to create a national germplasm resource bank for traditional Chinese medicine, with a goal to store over 100,000 resources by 2030 [6] Group 2: Research and Development Achievements - The laboratory has initiated 179 specialized projects in the seed industry, focusing on core technology breakthroughs and the cultivation of strategic new varieties [3][6] - A notable achievement includes the development of China's first Class II new veterinary drug, which serves as a substitute for feed antibiotics, contributing to food safety [7][8] Group 3: Economic Impact - The extraction of the plant-based feed additive has generated $15.85 million in export revenue and has gained recognition in both domestic and EU markets [8] - The establishment of the "Xiang Jiu Wei" public brand for traditional Chinese medicine has significantly enhanced the visibility and reputation of local medicinal materials [9] Group 4: Future Directions - The laboratory is set to tackle the challenges of deep processing and comprehensive utilization of the betel nut industry over the next 7 to 10 years [9] - The laboratory has developed a comprehensive innovation matrix, including 4 functional research departments and 15 variety creation centers, targeting urgent industry needs and future directions [11]